Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Rangering i aksjer #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Aksjekurs
$2.35
Sist synkronisert: 2022-09-07
Markedsverdi
$162.94K
Endring (1 dag)
2.17%
Endring (1 år)
0.00%
Land
US
Handel Brickell Biotech, Inc. (BBI)

Kategori

Aksjeprishistorikk for Brickell Biotech, Inc. (BBI)
Høyeste sluttskurs: $2.40 den 2022-09-01

Laveste sluttskurs: $194.34 den 2019-09-01
Aksjeprishistorikk for Brickell Biotech, Inc. fra 2019 til 2026
Årlig aksjeprisytelse
År Ytelse
2022 -80.40%
2021 -62.42%
2020 -56.44%
2019 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE